Key Insights

Highlights

Success Rate

79% trial completion

Published Results

11 trials with published results (22%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.0%

5 terminated out of 50 trials

Success Rate

79.2%

-7.3% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

58%

11 of 19 completed with results

Key Signals

11 with results79% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (7)
Early P 1 (2)
P 1 (14)
P 2 (15)
P 3 (3)

Trial Status

Completed19
Recruiting12
Terminated5
Unknown4
Active Not Recruiting4
Withdrawn3

Trial Success Rate

79.2%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (50)

Showing 20 of 20 trials
NCT05092451Phase 1Recruiting

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT04872595Phase 2Active Not Recruiting

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

NCT03849651Phase 2Active Not Recruiting

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

NCT06656494Phase 1Recruiting

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NCT07516847Phase 2Not Yet RecruitingPrimary

Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

NCT07355478Not Yet RecruitingPrimary

Asia Myelodysplastic Syndrome (MDS) Registry

NCT06465953Phase 3Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT02775383CompletedPrimary

The National Myelodysplastic Syndromes (MDS) Study

NCT06765876Early Phase 1Recruiting

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT07319793Not ApplicableNot Yet Recruiting

Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT

NCT07238712Phase 2Recruiting

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

NCT04064060Phase 3RecruitingPrimary

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT06398457Early Phase 1Recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT05884333Phase 2Recruiting

Cord Blood Transplant in Adults With Blood Cancers

NCT01660607Phase 1Completed

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

NCT02942290Phase 1Active Not RecruitingPrimary

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

NCT04898790Not ApplicableRecruiting

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

NCT06971185Active Not RecruitingPrimary

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

NCT06886425Not ApplicableRecruitingPrimary

Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

NCT06764511RecruitingPrimary

Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome

Scroll to load more

Research Network

Activity Timeline